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Abstract:  
By means of docking studies, seventeen compounds T.1-T17 have been designed and 
evaluated as multitarget inhibitors of VEGFR-2 and PD-L1 proteins in order to overcome 
resistance phenomena offered by cancer. All these designed molecules display a urea 
moiety as a common structural feature and eight of them (T.1-T8) further contain a 1,2,3-
triazol moiety. The antiproliferative activity of these molecules on several tumor cell lines 
(HT-29, MCF-7, HeLa, A549, HL-60), on the endothelial cell line HMEC-1 and on the 
non-tumor cell line HEK-293 has been determined. The urea derivatives were also 
evaluated for their antiangiogenic properties, whereby their ability to inhibit 
tubulogenesis and kinase activity employing flow cytometry, ELISA, 
immunofluorescence and western blot techniques was measured. In addition, these 
techniques were also employed to investigate the immunomodulator action of the 
synthetic compounds on the inhibition of PD-L1 and c-Myc proteins. Compound T.2, 1-
(3-chlorophenyl)-3-(2-(4-(4-methoxybenzyl)-1H-1,2,3-triazol-1-yl)ethyl)urea, has 
shown similar results to sorafenib in both down-regulation of VEGFR-2 and inhibition of 
the kinase activity of this receptor. Furthermore, compound T.14, (E)-1-(4-
chlorophenyl)-3-(3-(4-methoxystyryl)phenyl)urea, improves the effect of T.2 as regards 
tube formation of endothelial cells and inhibition of VEGFR-2 tyrosine kinase activity. 
In addition, T.14 improves the effect of the experimental drug BMS-8 in the inhibition of 
PD-L1 and c-Myc proteins. 
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ABSTRACT 
By means of docking studies, seventeen compounds T.1-T17 have been designed and 
evaluated as multitarget inhibitors of VEGFR-2 and PD-L1 proteins in order to overcome 
resistance phenomena offered by cancer. All these designed molecules display a urea 
moiety as a common structural feature and eight of them (T.1-T8) further contain a 1,2,3-
triazol moiety. The antiproliferative activity of these molecules on several tumor cell lines 
(HT-29, MCF-7, HeLa, A549, HL-60), on the endothelial cell line HMEC-1 and on the 
non-tumor cell line HEK-293 has been determined. The urea derivatives were also 
evaluated for their antiangiogenic properties, whereby their ability to inhibit 
tubulogenesis and kinase activity employing flow cytometry, ELISA, 
immunofluorescence and western blot techniques was measured. In addition, these 
techniques were also employed to investigate the immunomodulator action of the 
synthetic compounds on the inhibition of PD-L1 and c-Myc proteins. Compound T.2, 1-
(3-chlorophenyl)-3-(2-(4-(4-methoxybenzyl)-1H-1,2,3-triazol-1-yl)ethyl)urea, has 
shown similar results to sorafenib in both down-regulation of VEGFR-2 and inhibition of 
the kinase activity of this receptor. Furthermore, compound T.14, (E)-1-(4-
chlorophenyl)-3-(3-(4-methoxystyryl)phenyl)urea, improves the effect of T.2 as regards 
tube formation of endothelial cells and inhibition of VEGFR-2 tyrosine kinase activity. 
In addition, T.14 improves the effect of the experimental drug BMS-8 in the inhibition of 
PD-L1 and c-Myc proteins. 
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Cancer is a complex pathological process that encompasses a large group of diseases. 
There is a need therefore to find new drugs able to interfere with most of these processes 
in order to increase treatment options and to avoid resistance mechanisms.[1] The goal of 
the present work is the design, synthesis and biological evaluation of molecules with 
anticancer activity deemed to address two different biological targets of particular 
relevance in the cancer process. These targets are the tyrosin kinase VEGFR-2 (Vascular 
Endothelial Growth Factor Receptor 2) and the PD-L1 protein (Programmed Death-
Ligand 1). 
The first target is related to the angiogenesis process, the growth of new blood vessels 
from pre-existing vasculature, which is a critical step in tumor progression.[2] Vascular 
endothelial growth factors (VEGFs) regulate angiogenesis by binding to their associated 
receptors. Therapeutic inhibition of VEGFR-2 action is now having an impact in the 
clinical use for the treatment of a number of diseases.[3] The second target is related to 
the immunosuppressive ability of tumor cells. These overexpress negative immunologic 
regulators and generate a protected environment. The PD-L1 protein, which is 
overexpressed in cancer cells, plays a key role in the deregulation of the immune system 
through formation of PD-1/PD-L1 complex.[4] The present research intends to design 
compounds with the ability to bind to PD-L1 present in tumor cells, therefore blocking 
their ability to evade the immune system. Antibodies targeting the PD-1/PD-L1 immune 
checkpoint have achieved outstanding success in recent years. Clinically available 
examples include nivolumab and pidilizumab. However, their high immunogenicity and 
low stability have led to the research for new non-peptidic molecules.[5]  
It has been reported that the c-Myc oncogene has a direct role in preventing immune 
cells from efficiently attacking tumor cells. Indeed, c-Myc fosters tumor growth by 
increasing the levels of two immune checkpoint proteins, CD47 and PD-L1, which help 
thwart the host immune response.[6] Thus, c-Myc inactivation in tumors appears to 
engage the immune system to elicit cellular senescence in tumor cells and to collapse the 
vascular endothelial cells.[7] 
Sorafenib (Figure 1) is an inhibitor of the kinase domain of VEGFR-2. It bears a N,N´-
diarylurea fragment that has shown, both through X-ray diffraction studies [8] and 
through computational studies [9], to be determinant in its interaction with the kinase 
domain. Docking studies have revealed that sorafenib can form 5 hydrogen bonds with 
the kinase domain of VEGFR-2: two with Glu885, two weak links with Cys919 and one 
with Asp1046. The other interactions with the kinase domain are of the hydrophobic type 
with the pocket formed by the amino acids Leu840, Val848, Ala866, Ile888, Leu889, 
Val899, Phe918, Thr916 and Leu1035. It has also been established that the strongest link 
is formed with the Asp1046. 
Brystol-Myers Squibb reported in 2015 the discovery of the first non-peptidic 
molecules able to inhibit the formation of the PD-1/PD-L1 complex [10]. The mode of 
interaction of these compounds, indicated as BMS-8, BMS-37, BMS-202 and BMS-242 
in Figure 1, was established in 2016 [11]. Using differential scanning fluorimetry (DSF) 
techniques, it was determined that these compounds induce thermal stabilization of PD-
L1. Finally, the protein bound to the substrates was crystallized and the binding sites 
determined. Thus, these compounds are linked in a hydrophobic groove formed by the 
amino acids Tyr56, Met115, Ile116, Ala121 and Tyr123 and promote the dimerization of 
PD-L1 protein. Thus, it is possible to inhibit the formation of the PD-1/PD-L1 complex 
by means of a double pathway: the inhibitors occupy part of the area involved in the PD-
1/PD-L1 interaction and, in addition, when the dimer is formed between two PD-L1 
molecules, one of them has the opposite orientation to the one necessary to interact with 
PD-1. Consequently, the interaction between PD-1 and PD-L1 is disabled. 
 
Figure 1. Structure of sorafenib and non-peptidic inhibitors of PD-L1. 
Both the binding site of sorafenib in the kinase domain of VEGFR-2 and the binding 
site in PD-L1 possess a hydrophobic groove in which aromatic rings can be inserted. Our 
goal is the design of compounds able to interact with both binding sites and act as 
multitarget inhibitors. 
2. Results and discussions 
2.1. Preliminary docking study 
We have carried out a docking study using AutoDock 4.2 software [12] on the kinase 
domain of VEGFR-2 and on the site identified in PD-L1 in order to locate relatively 
simple structures that are able to interact with both sites. Several general structures 
capable of establishing at least three of the hydrogen bonds shown by sorafenib (see 
Figure 2) and of interacting with the binding site in PD-L1 have been identified by us. 
These structures are characterized by having a urea system (which is essential to allow its 
interaction with the kinase domain) to which aromatic rings are bound in order to interact 
with the hydrophobic grooves present in both proteins. 
 
Figure 2. Identified general structures able to interact with the kinase domain of VEGFR-
2 and PD-L1. The hydrogen bonds that can be formed with VEGFR-2 are indicated in 
red. The zones of the molecules that interact with the hydrophobic pockets of both binding 
sites are also indicated. 
 
As an example, the docking obtained for three of the analyzed structures is shown in 
Figure 3. It can be appreciated in Figure 3A that compounds D.1, D.2 and D.3 occupy the 
binding site in the kinase domain of VEGFR-2 in much the same way as sorafenib does. 
These compounds establish hydrogen bonds between the OMe group and Cys919, 
between the two NH groups of the urea system and Glu885 and between the O of urea 
and Asp1046. The three aromatic rings interact with two hydrophobic zones present in 
the binding site. It can be seen in Figure 3B that structures D.1, D.2 and D.3 also occupy 
the binding site of BMS-202 in PD-L1 protein. The aromatic rings are inserted in a 
hydrophobic groove with the A rings establishing interactions with Tyr56, Me115 and 
Ala121, whereas ring B interacts with Tyr123. The more polar urea system points towards 
the outer zone of the groove. 
 
 
Figure 3. A) Superposition of D.1 (orange), D.2 (light blue), D.3 (green) and sorafenib 
(grey) in the kinase domain of VEGFR-2. B). Superposition of D.1 (orange), D.2 (light 
blue), D.3 (green) and BMS-202 (violet) at the PD-L1 binding site. 
With the objective to verify these preliminary results obtained from the in-silico study, 
we envisaged the synthesis and the biological evaluation of several compounds derived 
from the general structures D.4-D.7 shown in Figure 4. Additionally, differential scanning 
fluorometry and free protein detection by ELISA were performed prior to the 
development of the corresponding cellular assays in order to verify the interaction 
between the targets of study and the designed compounds (see Supporting Information 
S2 and S3). 
 
Figure 4. Potential multitarget inhibitors of VEFGR-2 and PD-L1. 
2.2.Synthetic work of triazolyl-ureas T.1-T.8 
To begin with, we decided to synthesize triazoles with the general structure D.4 due to 
its easy synthetic accessibility. These compounds were obtained in only two synthetic 
steps from 2-azidoethan-1-amine 1 as indicated in Scheme 1 [13]. Thus, treatment of 
azidoamine 1 with carbonyl diimidazole in the presence of triethylamine generated the 
corresponding imidazolide which was then allowed to react with a range of anilines to 
afford azido-ureas 2-9. These were then converted into triazolyl-ureas T.1-T8 upon 
copper-catalyzed 1,3-dipolar cycloaddition [14] with 1-methoxy-4-(prop-2-yn-1-
yl)benzene (for the preparation of this compound see the Experimental section). 
 
Scheme 1 
Reagents and conditions: (a) CDI, Et3N, DMF, 3 h, rt, then the appropriate aniline, 50ºC, 
overnight; (b) 1-methoxy-4-(prop-2-yn-1-yl)benzene, CuSO4·5H2O, sodium ascorbate, 
DMF/H2O (9/1), 60ºC, 2 h. 
 
Unfortunately, all attempts to prepare the ortho-halogenated isomers failed due 
probably to the steric hindrance caused by the halogen in ortho position. 
 
2.3.Biological evaluation of triazolyl-ureas T.1-T.8 
2.3.1. Cell proliferation inhibition 
The ability of triazolyl-ureas T.1-T.8 to inhibit cell proliferation was established by 
means of their IC50 values towards the human tumor cell lines HT-29 (colon 
adenocarcinoma), MCF-7 (breast adenocarcinoma), HeLa (epithelioid cervix carcinoma) 
and A549 (pulmonary adenocarcinoma), as well as towards the endothelial cell line 
HMEC-1 (human microvascular endothelial cells) and the non-tumor cell line HEK-293 
(human embryonic kidney cells). All the IC50 values observed were higher than 200 μM 
in all the cell lines tested and are not listed here. 
2.3.2. Effect on cellular VEGFR-2 
The effect of compounds T.1-T.8 on VEGFR-2 in HMEC-1 cell line was determined 
by flow cytometry technique. For this assay, cells were incubated for 24 hours in the 
presence of the corresponding compounds at 100 µM concentration. Then, cells were 
fixed with formaldehyde and treated with anti-VEGFR-2-alexafluor®647 to quantify 
membrane VEGFR-2 by flow cytometry. On the other hand, permeabilization of cells 
with Triton X-100 prior to fixation step, allowed the quantification of total VEGFR-2 in 
cells.  Table 1 shows the effect of the selected derivatives on VEGFR-2 expression and 
distribution in HMEC-1 endothelial cell line, referred to control (DMSO, 100%). 






Sorafenib 46 ± 8 64 ± 4 
T.1 97 ± 14 105 ± 10 
T.2 74 ± 6 81 ± 14 
T.3 90 ± 4 102 ± 5 
T.4 79 ± 10 78 ± 1 
T.5 40 ± 10 55 ± 5 
T.6 79 ± 9 100 ± 11 
T.7 76 ± 4 91 ± 9 
T.8 97 ± 15 90 ± 7 
Data are the average (±SD) of three experiments. 
Results from Table 1 indicate that compound T.5 (p-Br) is the derivative that shows 
the strongest interaction with VEGFR-2 in HMEC-1 cells, improving the effect exerted 
by sorafenib. Some of the other compounds (T.2, T.4, T.6, T.7) were also able to down-
regulate the expression of VEGFR-2 but to a lesser extent. 
Table 2 depicts the effect of T.2, T.4 and T.5 on VEGFR-2 expression and distribution 
in A549 tumor cell line at 100 µM concentration, referred to control (DMSO, 100%). 






Sorafenib 92 ± 3 85 ± 5 
Sunitinib 66 ± 8 135 ± 14 
T.2 95 ± 3 86 ± 6 
T.4 98 ± 6 80 ± 8 
T.5 70 ± 4 61 ± 11 
Data are the average (±SD) of three experiments. 
Results from Table 2 indicate again that T.5 (p-Br) is the derivative that shows the 
strongest interaction with VEGFR-2 in A549 cells improving the effect exerted by the 
reference compound. 
2.3.3. Inhibition of VEGFR-2 kinase activity 
The interaction VEGF/VEGFR-2 causes phosphorylation of the receptor and triggers 
the signaling cascade that promotes phosphorylation of Erk1/2 (extracellular signal-
regulated kinase) and, subsequently, activation of the angiogenesis process [15]. 
In view of the fact that triazolyl-ureas T.1-T.8 interact with VEGFR-2 on endothelial 
cells, their capacity to inhibit kinase activity was also studied. Thus, HMEC-1 cells were 
treated with the derivatives for 24 h at 100 µM, then the cells were lysed and phospho-
VEGFR-2 was quantified by ELISA analysis. Western blot analysis of the compounds 
that were active in inhibiting phospho-VEGFR-2 allowed the relative quantification of 
phospho-Erk1/2. Table 3 shows the percentage of p-VEGFR-2 and p-Erk for each 
compound referred to control (DMSO, 100%). 






Sorafenib 77 ± 9 80 ± 8 
T.1 100 ± 12 - 
T.2 70 ± 16 38 ± 14 
T.3 86 ± 3 72 ± 6 
T.4 >100 - 
T.5 >100 - 
T.6 83 ± 4 82 ± 11 
T.7 90 ± 10 - 
T.8 >100 - 
Data are the average (±SD) of three experiments. 
 
Figure 5. Representative Western blot of p-Erk1/2 detection in HMEC-1 cells. β-actin 
was used as internal control. 
 
Table 3 shows that the best inhibitory kinase activity in endothelial cells is shown by 
T.2 (m-chloro), T.3 (p-chloro) and T.6 (o-methyl) which are able to reduce the 
phosphorylation of VEGFR-2 at levels similar to sorafenib. Interestingly, there is an 
important inhibition of Erk1/2 phosphorylation by T.2, improving the results obtained 
with sorafenib. 
On the other hand, inhibition of VEGFR-2 kinase activity in A549 cells was also tested 
but in this case, none of the selected derivatives improved the effect observed for 
sorafenib. Table 4 shows the percentage of p-VEGFR-2 and p-Erk for each compound 
referred to control (DMSO, 100%). 






Sorafenib 84 ± 4 50 ± 7 
T.2 121 ± 11 99 ± 9 
T.3 125 ± 12 78 ± 7 
T.6 121 ± 16 119 ± 8 
T.7 112 ± 10 90 ± 13 
Data are the average (±SD) of three experiments. 
 
Figure 6. Representative Western blot of p-Erk1/2 detection in A549 cells. β-actin was 
used as internal control. 
2.3.4. Tube formation inhibition on endothelial cells 
Antiangiogenic agents mainly affect endothelial cells. Thus, the capacity of synthetic 
compounds to inhibit the formation of new vasculature network formed by HMEC-1 was 
evaluated. Therefore, cells were seeded on top of Matrigel® and simultaneously treated 
with different concentrations of derivatives. Pictures were taken 24 h later in order to 
evaluate the tube formation inhibition effect. Table 5 shows the minimum concentration 
at which compounds are active in the tube formation inhibition. Only T.2, T.3 and T.6 
were tested, since they showed the highest activities in the inhibition of VEGFR-2 kinase 
activity (see Table 3). 
Table 5. Inhibition effect of tube formation. 
Comp. 
Minimum  






Data are representative of three experiments. 
Data from Table 5 confirm that triazolyl-ureas are able to inhibit tube formation but at 
higher doses than sunitinib and sorafenib, with T.2 (m-chloro) being the most potent 
compound. 
2.3.5. Effect on PD-L1 and c-Myc proteins 
In order to evaluate the immunomodulator properties of the synthetic derivatives, the 
effect on PD-L1 and c-Myc proteins by the selected compounds was studied. Thus, 
compounds were added to A549 cells at 100 μM concentration and, after 24 h, cells were 
lysed and ELISA analysis was performed to determine the relative amount of both 
proteins compared to DMSO treated cells. Table 6 shows the percentage of free PD-L1 
detected for each compound referred to control (DMSO). The percentage of c-Myc has 
been quantified only for the compounds which exerted a similar or better action than the 
reference compound BMS-8 in the inhibition of PD-L1. 
Table 6. PD-L1 and c-Myc detection in A549 cells. 
Comp. % PD-L1 % c-Myc 
BMS-8 68 ± 5 60 ± 7 
T.1 83 ± 9 - 
T.2 70 ± 8 60 ± 8 
T.3 69 ± 10 73 ± 5 
T.4 80 ± 12 - 
T.5 >100 - 
T.6 82 ± 20 - 
T.7 90 ± 20 - 
T.8 66 ± 6 70 ± 8 
Data are the average (±SD) of three experiments. 
From Table 6 it can be concluded that compounds T.2 (m-chloro), T.3 (p-chloro) and 
T.8 (p-methyl) inhibit PD-L1 and c-Myc proteins in a similar way to BMS-8. 
2.3.6. Cell proliferation evaluation in co-cultures 
Some tumor cell lines such as A549 and HT-29 show high PD-L1 overexpression.[16] 
Therefore, cell proliferation of these has been studied in presence of PD-1 expressing 
Jurkat T cells in order to evaluate whether the observed cell proliferation inhibition is due 
to the blockage of PD-1/PD-L1 system. Compounds which showed good PD-L1 
inhibition in ELISA test were evaluated. Thus, tumor cells were treated for 24 h with the 
selected compounds at 200 µM in presence of Jurkat T cells and then, living cells were 
counted using trypan blue and a Neubauer chamber. Figure 7 shows the inhibition of 
tumour cell proliferation exhibited by the derivatives due to the presence of Jurkat T cells. 
 
Figure 7. Inhibition of cell proliferation (%) in presence of Jurkat T cells. Data are 
representative of three experiments. 
From data provided in Figure 7, it can be concluded that the tested compounds are able 
to inhibit A549 cell proliferation in co-culture but do no improve the effect exerted by 
BMS-8. Interestingly, in the HT-29 cell line this effect is much higher for compounds T.2 
(m-chloro) and T.3 (p-chloro), improving the effect exhibited by BMS-8. 
 
2.4. Synthesis of ureas T.9-T.17 
The triazolyl-ureas that contain a chlorine atom in their structure are the compounds 
that display the best activities in our biological tests and these were very similar to the 
ones exhibited by our reference compounds sorafenib and BMS-8. Therefore, we decided 
to prepare new compounds with general structures D.5-D.7 (Fig. 4) containing a chlorine 
atom in the phenyl ring. The synthesis of these compounds is depicted in Scheme 2. Thus, 
Wittig reaction of phosphonium salt 11 with 4-methoxybenzaldehyde afforded 1-(4-
methoxystyryl)-3-nitrobenzene 12 as a mixture of E/Z isomers. Reduction of this mixture 









Inhibition of cell proliferation (%)
BMS-8 T.2 T.3 T.8
afford (Z)-3-(4-methoxystyryl)aniline 13 and (E)-3-(4-methoxystyryl)aniline 14. On the 
other hand, hydrogenation of 12 led to 3-(4-methoxyphenethyl)aniline 15. Compounds 
13, 14 and 15 were converted into carbamates 16, 17 and 18 [17], which upon reaction 
with chloroanilines gave rise to ureas T.9-T.17. 
 
Scheme 2 
Reagents and conditions: (a) PPh3, CH2Cl2, 3 h, rt., 71%; (b) 4-methoxybenzaldehyde, 
K2CO3, 18-crown-6, CH2Cl2, reflux, overnight, 73%; (c) Zn, AcOH, 1 h, rt., (Z/E 6:4); 
(d) H2, Pd/C, EtOAc, 2 h, rt., 66%; (e) phenyl chloroformate, pyridine, THF, 0ºC 30 min, 
then 1 h rt.; (f) the appropriate chloroaniline, Et3N, THF, 40-50ºC. 
 
2.5. Biological evaluation of ureas T.9-T.17 
2.5.1. Cell proliferation inhibition 
The ability of ureas T.9-T.17 to inhibit cell proliferation was established by means of 
their IC50 values towards the human tumor cell lines HT-29 (colon adenocarcinoma), 
MCF-7 (breast adenocarcinoma), HeLa (epithelioid cervix carcinoma) and A549 
(pulmonary adenocarcinoma), as well as towards the endothelial cell line HMEC-1 
(human microvascular endothelial cells) and the non-tumor cell line HEK-293 (human 
embryonic kidney cells). The IC50 values for ureas T.9-T.17 are presented in Table 7 
along with IC50 values for the reference compounds sunitinib, sorafenib and BMS-8. 
 
Table 7. IC50 values (μM) for sunitinib, sorafenib, BMS-8 and derivatives T.9-T.17.
a 
Comp. HT-29 MCF-7 HeLa A549 HMEC-1 HEK-293 
Sunitinib 3.8 ± 0.5 0.08 ± 0.02 7.8 ± 1.0 11 ± 2 7 ± 4 5.0 ± 0.8 
Sorafenib 17 ± 4 14 ± 4 6.1 ± 0.4 27 ± 2 34 ± 3 5.0 ± 0.7 
BMS-8 19 ± 2 20 ± 3 >100 6 ± 1 - 60 ± 10 
T.9 12 ± 4 19 ± 2 22 ± 3 21 ± 9 33.0 ± 0.6 6.5 ± 0.2 
T.10 20 ± 10 37.2 ± 0.8 10.5 ± 0.6 38 ± 3 32.9 ± 0.5 5 ± 2 
T.11 33 ± 5 17 ± 3 8 ± 1 29 ± 3 33 ± 3 20 ± 10 
T.12 47 ± 4 >100 >100 61 ± 3 >100 57 ± 3 
T.13 3.5 ± 0.6 4.3 ± 0.7 11.3 ± 0.7 7.7 ± 0.2 2 ± 1 2.4 ± 0.6 
T.14 0.52 ± 0.09 0.40 ± 0.09 0.7 ± 0.3 1.5 ± 0.9 1.8 ± 0.8 1.0 ± 0.4 
T.15 20 ± 3 >100 69 ± 5 24 ± 5 48 ± 7 90 ± 10 
T.16 14 ± 4 8.2 ± 0.6 16.5 ± 0.7 >200 50 ± 20 5.3 ± 0.9 
T.17 1.5 ± 0.1 15.3 ± 0.4 21 ± 1 >200 >200 1.8 ± 0.7 
aIC50 values are expressed as the compound concentration that inhibits the cell growth by 50%. Data are the average 
(±SD) of three experiments. 
The synthetic ureas show antiproliferative activity in the low micromolar range in all 
tested cell lines, comparable to that shown by reference compounds sunitinib, sorafenib 
and BMS-8. The (E)-p-chloro derivative T.14 was the most active one with IC50 values 
at submicromolar level, and exhibited lower IC50 values in cancer cell lines than in non-
tumour endothelial ones. This fact allowed us to study the biological activity of this 
compound at a concentration that does not affect non-tumour cell lines. 
2.5.2. Induction of apoptosis 
Apoptosis represents a universal and exquisitely efficient cellular suicide pathway 
[18]. This phenomenon can be triggered by intrinsic signals such as genotoxic stress, or 
extrinsic signals such as the binding of ligands to cell surface death receptors [19]. 
Induction of apoptosis was studied by measuring the translocation of phosphatidylserine 
from the cytoplasmic to the extracellular side of the plasma membrane. Thus, A549 cells 
were incubated for 24 h in the presence of compounds at 100 µM, after which annexin-V 
binding was measured by flow cytometry. The apoptotic effect of compounds T.9-T.17 
is indicated in Figure 8. 
 
Figure 8. Apoptotic effect (%) in A549 cells. Data are representative of three experiments. 
All the tested compounds induce apoptosis at 100 µM, with the exception of compound 
T.10, which exhibited an activity similar to that of control (DMSO). Moreover, 
compounds T.11, T.13, T.15, T.16 and T.17 improve the effect depicted by sunitinib and 
sorafenib. BMS-8 and T.1-T.8 derivatives were also tested but they did not exhibit any 
effect in the induction of apoptosis. 
2.5.3. Effect on cellular VEGFR-2 
The effect of ureas T.9-T.17 on VEGFR-2 in A549 tumor cell line was determined by 
both flow cytometry and immunofluorescence techniques. For these assays, cells were 
incubated for 24 hours in the presence of the corresponding compounds at 10 µM 
concentration. Table 8 and Figure 7 show the results obtained for each compound on free 
VEGFR-2 presence and distribution in A549 cell line, referred to control (DMSO). 






Sorafenib 92 ± 3 85 ± 5 
Sunitinib 66 ± 8 135 ± 14 
T.9 114 ± 20 177 ± 9 
T.10 102 ± 10 186 ± 10 
T.11 118 ± 3 100 ± 7 













C Suni. Sora. T.9 T.10 T.11 T.12 T.13 T.14 T.15 T.16 T.17
Apoptotic cells (%)
T.13 52 ± 10 32 ± 4 
T.14 56 ± 11 10 ± 2 
T.15 100 ± 19 100 ± 16 
T.16 97 ± 10 98 ± 3 
T.17 97 ± 11 96 ± 7 
Data are the average (±SD) of three experiments. 
(E) derivatives T.13 (m-chloro) and T.14 (p-chloro) were the best ones in reducing the 
presence of VEGFR-2, therefore improving the effect exerted by sorafenib. Indeed, they 
were able to down-regulate VEGFR-2 to the half of the control inhibiting internalization 
of the target and reducing the total level of the protein to 10-30 % of the control. 
Immunofluorescence assay correlated well with flow cytometry results. Figure 9 
shows that both compounds T.13 (B) and T.14 (C) caused a significant reduction of 
membrane VEGFR-2 and compound T.14 exerted a higher inhibition of the 
internalization of the protein to the nucleus. 
 
Figure 9. Effect on VEGFR-2 expression in A549 cells (A) DMSO, (B) T.13 and (C) 
T.14. 
The effect of (E) derivatives on VEGFR-2 presence and distribution in endothelial cells 
was also evaluated (see Table 9), referred to control (DMSO). 






Sorafenib 46 ± 8 64 ± 4 
T.12 76 ± 9 121 ± 8 
T.13 55 ± 8 106 ± 16 
T.14 56 ± 8 109 ± 17 
Data are the average (±SD) of three experiments. 
 
Results from Table 9 indicate that the (E) derivatives did not inhibit internalization of 
VEGFR-2 in HMEC-1 cells but reduced the presence of the target in the membrane. 
Again, T.13 and T.14 exhibited the highest activities, similar to sorafenib. 
2.5.4. Inhibition of VEGFR-2 kinase activity 
The effect on kinase activity of VEGFR-2 exerted by the (E) derivatives was studied 
by western blot on two cell lines, A549 and HMEC-1. In this case, cells were treated for 
24 h at 10 µM concentration of the corresponding compounds. Table 10 shows the relative 
amount of p-VEGFR-2 and p-Erk1/2 detected on A549 when treated with each compound 
referred to control (DMSO). 






Sorafenib 84 ± 4 50 ± 7 
T.12 76 ± 3 100 ± 18 
T.13 75 ± 5 56 ± 12 
T.14 82 ± 3 66 ± 8 
Data are the average (±SD) of three experiments. 
 
Figure 10. Representative Western blot of p-Erk1/2 detection in A549 cells. β-actin was 
used as internal control. 
 
Table 10 shows that T.13 and T.14 reduce VEGFR-2 and Erk1/2 phosphorylation in 
the tumor cell line in a similar way to sorafenib. However, no effect on the kinase activity 
of VEGFR-2 on the endothelial cell line HMEC-1 was observed for any of the tested 
compounds. 
2.5.5. Tube formation inhibition on endothelial cells 
The capacity of ureas T.9-T.17 to inhibit the formation of new vasculature network 
formed by HMEC-1 was evaluated. Table 11 shows the minimum concentration at which 
compounds are active and begin to inhibit the microtube formation. 
Table 11. Inhibition effect of tube formation. 
Comp. 
Minimum  












Data are representative of three experiments. 
A comparison of the minimum active concentration values to IC50 values for HMEC-
1 cell line (see Table 7) shows that there is a correlation between antiproliferative activity 
and tube formation inhibition capacity, as compounds with lower IC50 values exhibit 
microtube inhibition activity at lower concentrations. Moreover, it is observed that some 
of the tested compounds are more active than sunitinib and sorafenib, particularly (E) 
derivatives T.13 (m-chloro) and T.14 (p-chloro), which are 100-fold more active than 
sorafenib. Pictures for the inhibition of neovascularization achieved by compound T.14, 
at different concentrations, are displayed in Figure 11. 
 
Figure 11. Effect of T.14 at 1, 0.1 and 0.01 µM concentrations (from left to right). 
2.5.6. Effect on PD-L1 and c-Myc proteins 
We also evaluated the immunomodulator properties of these derivatives in the same 
way as described above for the triazole derivatives. Thus, the effect on PD-L1 and c-Myc 
proteins by the selected compounds was studied by ELISA on A549 cells. After 24 h 
treatment at 100 μM concentration of compounds, cells were lysed and ELISA analysis 
was performed to determine the relative amount of both proteins compared to DMSO 
treated cells. Table 12 shows the percentage of free PD-L1 detected for each compound 
referred to control (DMSO). Again, the percentage of c-Myc has been quantified only for 
the compounds which exerted similar or better action than the reference compound BMS-
8 in the inhibition of PD-L1. 
Table 12. PD-L1 and c-Myc proteins detection in A549 cells. 
Comp.a % PD-L1 % c-Myc 
BMS-8 68 ± 5 60 ± 7 
T.9 83 ± 3 - 
T.10 92 ± 10 - 
T.11 75 ± 6 - 
T.12 74 ± 7 - 
T.13 49 ± 8 65 ± 12 
T.14 25 ± 9 37 ± 5 
T.15 61 ± 6 63 ± 11 
T.16 51 ± 9 51 ± 10 
T.17 38 ± 3 44 ± 6 
a T.9-T.14 were tested at 15 µM. BMS-8 and T.15-T.17 were tested at 100 µM. Data are the average (±SD) 
of three experiments. 
From Table 12 it can be deduced that compounds T.13, T.14, T.16 and T.17 are able 
to inhibit PD-L1 and c-Myc proteins and display a stronger effect than that exerted by 
BMS-8, with T.14 (p-chloro) being the most active in both targets. 
Subsequently, immunofluorescence was performed for compound T.14. For this assay, 
cells were incubated for 24 hours at 100 µM of treatment. Then, cells were fixed, 
permeabilized and treated with anti-PD-L1-alexafluor®647 and anti-c-Myc-FITC. The 
pictures shown in Figure 12 correlate well with the results obtained by ELISA test (Table 
12), since compound T.14 (C) inhibits PD-L1 and c-Myc proteins in a higher proportion 
than BMS-8 (B). 
 
Figure 12. Effect on PD-L1 (red) and c-Myc (green) in A549 cells. (A) DMSO, (B) BMS-
8, (C) T.14. 
2.5.7. Cell proliferation evaluation in co-cultures 
We also studied the effect of compounds T.13, T.14 and T.17, which showed good 
PD-L1 inhibition, in affecting tumor cell proliferation in the presence of PD-1 expressing 
Jurkat T-cells. Thus, A549 were treated for 24 h with the selected compounds at 200 µM 
in presence of Jurkat T cells. Then, living cells were counted using trypan blue and a 
Neubauer chamber. Figure 13 shows the inhibition of tumor cell proliferation exhibited 
by T.13, T.14 and T.17 due to the presence of Jurkat T cells. 
 
 
Figure 13. Inhibition of cell proliferation (%) in presence of Jurkat T cells. Data are 
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Data provided in Figure 13 shows that T.13 and T.14 were able to inhibit A549 cell 
proliferation in co-culture improving the effect exerted by BMS-8. Therefore, it can be 
affirmed that these derivatives act by means of disturbing PD-1/PD-L1 interactions. 
3. Summary and conclusions 
The biological study of triazolyl ureas T.1-T.8 has revealed that derivatives with 
chlorine substitution in meta or para positions of the benzene ring are the most active as 
antiangiogenic and immunomodulator agents. Indeed, T.2 (m-Cl) has proven very 
effective in both down-regulation of VEGFR-2 and inhibition of the kinase activity of 
this receptor, better results being observed than with the reference compounds. Regarding 
the immunomodulator properties, T.2 has been the most effective triazolyl urea in 
inhibiting cell proliferation in co-cultures, since due to its interaction with PD-L1 it has 
increased its antiproliferative effect in almost a 50%. 
In search of higher activities than those observed with the triazolyl ureas, we 
synthetized a second group of ureas (T.9-T.17) that lacked this structural fragment. These 
compounds have shown antiproliferative and apoptotic activity at lower doses than the 
triazolyl derivatives. In general, derivatives with (E) configuration in the stilbene subunit 
have been the most active ones improving the biological results obtained for the reference 
compounds. More specifically, T.13 (m-Cl) and T.14 (p-Cl) inhibit tube formation of 
endothelial cells at 0.1 μM and show inhibition of VEGFR-2 tyrosine kinase activity at 
lower concentrations than the triazolyl ureas and the reference compound BMS-8. As 
regards immunomodulator effect, they are able to improve the effect of BMS-8 in the 
inhibition of PD-L1 and c-Myc proteins. T.14 has been the most active stilbene urea in 
inhibiting cell proliferation in co-cultures, with an increase in antiproliferative effect of 
more than 80%. 
In summary, compounds T.2 (triazole, m-Cl), T.13 (E-stilbene, m-Cl) and T.14 (E-
stilbene, p-Cl) show the best antiangiogenic and immunomodulator properties for every 
group of synthetized compounds. This has let us to conclude that the presence of a 
chlorophenyl urea unit is important for the dual action of these kind of derivatives. Even 
so, a comparison of the results obtained for the triazolyl ureas with those achieved with 
the stilbene ureas has led us to conclude that the presence of the triazole ring in these aryl 
urea derivatives does not improve the biological activity when compared to the reference 
compounds. However, the substitution of the triazole ring for the E-stilbene unit leads to 
the enhancement of the expected dual biological activity. To the best of our knowledge, 
this is the first example of the design and synthesis of compounds with both anti-PD-L1 
and anti-angiogenic effect, so that a new door is opened to new kind of promising targeted 
anticancer agents. 
4. Experimental 
4.1. Docking studies 
Molecular docking was performed using Autodock 4.2 [12]. The crystal structures of 
the VEGFR-2 kinase domain (PDB ID: 3EWH) and PD-L1 (PDB ID: 4ZQK) were used 
as templates. Ligands were previously removed from the protein structure in order to 
perform docking simulation. Discovery Studio Visualizer program [20] was used to build 
the structures of ureas T.1-T.17. The cluster was compared on the basis of the free energy 
of binding. The Lamarckian genetic algorithm (LGA) was employed with the default 
parameters; g_eval was set to 2500000 (medium) and 100 LGA runs were conducted. 
Molecular graphics were done with PYMOL (PyMOL Molecular Graphics System, 
version 1.6).  
4.2. Chemistry 
4.2.1. General procedures 
NMR spectra were measured at 25°C. The signals of the deuterated solvent (CDCl3 or 
DMSO) were taken as the reference. Multiplicity assignments of 13C signals were made 
by means of the DEPT pulse sequence. Complete signal assignments in 1H and 13C NMR 
spectra were made with the aid of 2D homo- and heteronuclear pulse sequences (COSY, 
HSQC, HMBC). High resolution mass spectra were run by the electrospray mode 
(ESMS). IR data were measured with oily films on NaCl plates (oils) and are given only 
for relevant functional groups (C=O, NH). Experiments which required an inert 
atmosphere were carried out under dry N2 in flame-dried glassware. Commercially 
available reagents were used as received. 
4.2.2. Experimental procedure for the synthesis of 1-methoxy-4-(prop-2-yn-1-yl)benzene 
(4-methoxyphenyl)methanol (1 eq) was dissolved in CH2Cl2 (1.5 mL/mmol) and 
cooled at 0ºC. Then, PBr3 (1 eq) was slowly added and the mixture was stirred at 0ºC 
under inert atmosphere. After three hours, the mixture was poured over a saturated 
aqueous solution of NaHCO3 and extracted with CH2Cl2. The organic solvent was 
evaporated under reduced pressure and the crude residue was purified by means of flash 
silica gel chromatography (hexane) to afford 1-(bromomethyl)-4-methoxybenzene. The 
latter compound and CuCl (0.5 eq) were added to an ethynylmagnesium bromide (2 eq) 
solution 0.5 M in THF. The mixture was stirred at reflux (70ºC) for 2 h. The reaction 
mixture was then cooled and poured over a saturated aqueous solution of NH4Cl, followed 
by extraction (3 times) with Et2O. The organic phase was washed with H2O and brine and 
dried over anhydrous MgSO4. After evaporation of all volatiles under reduced pressure, 
the crude residue was purified by flash silica gel chromatography (hexane:EtOAc 
mixtures as eluent) to afford 1-methoxy-4-(prop-2-yn-1-yl)benzene as a yellowish oil (57%). 
4.2.3. Experimental procedure for the synthesis of azido-ureas 2-9. 
A solution of 2-azidoethan-1-amine 1 (1 eq) in DMF was treated with Et3N (2 eq). The 
solution was stirred for 10 min at rt and then CDI (2 eq) was added. The resulting mixture 
was stirred for 20 min at rt. Then, the corresponding aniline (2 eq) was added to the 
reaction mixture and this was stirred overnight at 50ºC. After this time, the solvent of the 
reaction mixture was evaporated under reduced pressure and the crude was purified by 
flash silica gel chromatography (hexane:EtOAc mixtures as eluent) to afford the desired 
products 2-9. 
4.2.4. Experimental procedure for the synthesis of triazolyl-ureas T.1-T.8. 
A solution of 1-methoxy-4-(prop-2-yn-1-yl)benzene (1 eq) in DMF was treated with the 
corresponding previously prepared azido-ureas (1.2 eq). Then, a mixture of CuSO4·5H2O 
(0.1 eq) and sodium ascorbate (0.1 eq) in DMF/H2O (9:1) was added to the reaction 
mixture which was stirred for 2 h at 60ºC. After that time, the mixture was concentrated, 
redissolved in EtOAc, and washed with brine repeated times. Finally, the organic solvent 
evaporated under reduced pressure and the crude was purified by flash silica gel 
(hexane:EtOAc mixtures as eluent) to afford the desired products. Detailed analytical data 
ate given in the Supplementary Material. 
4.2.5. Experimental procedure for the synthesis of phosphonium salt 11. 
A solution of 3-nitrobenzyl bromide D10 (4.63 mmol) and triphenylphosphine (4.63 
mmol) in dry CH2Cl2 (20 mL) was stirred for 3 h at rt. After the reaction was complete, 
the white precipitate was filtered and sequentially washed with CH2Cl2 and hexane 
affording 11 as a white solid (1.56 g, 71%, m. p. 273ºC). 
4.2.6. Experimental procedure for Wittig reaction (Scheme 2, b). 
4-methoxybenzaldehyde (3.26 mmol) was dissolved in CH2Cl2 (20 mL) and then, the 
phosphonium salt 11 (3.26 mmol), K2CO3 (3.6 mmol) and 18-crown-6 (0.6 mmol) were 
added to the solution. The mixture was refluxed overnight and then was filtered and 
concentrated affording 810 mg (73% yield) of compound 12 as an E/Z stereoisomeric 
mixture. 
4.2.7. Experimental procedure for nitro group reduction (Scheme 2, c). 
Zn (0.6 mol) was added to a solution of compound 12 (4.08 mmol) in AcOH (133 mL). 
The resulting mixture was vigorously stirred at rt for 1 h in a flask that was protected from 
the light. Then, the solids were filtered over Celite to remove the Zn, and were thoroughly 
washed with EtOAc. The filtrate was neutralized with saturated aqueous NaHCO3 and 
the organic phase was separated and dried over MgSO4 anhydride. After filtration and 
solvent evaporation, silica gel column chromatography (hexane-EtOAc mixtures as 
eluent) was used to isolate the stereoisomers 13 and 14 (Z/E 6:4). 
4.2.8. Experimental procedure for hydrogenation (Scheme 2, d). 
Compound 12 (2.35 mmol) was dissolved in EtOAc (30 ml) and stirred with 10 % Pd/C 
(300 mg) for 2 h at rt and ambient pressure under a hydrogen atmosphere. The resulting 
mixture was filtered through a pad of Celite and the filtrate was evaporated under reduced 
pressure. Then, the residue was purified by silica gel column chromatography (hexane-
EtOAc mixtures as eluent) to give compound 15 as a brownish solid (66%, m. p. 81-
85ºC). 
4.2.9. Experimental procedure for the synthesis of carbamates 16-18. 
A solution of 13, 14 or 15 (1 eq.) in THF (5 mL/mmol) was cooled at 0ºC and anhydrous 
pyridine (2.4 eq.) and phenyl chloroformate (1.4 eq.) was added under inert atmosphere. 
The resulting mixture was stirred in the dark for 20 min at 0ºC and then for 1 h at rt. After 
this time, H2O (5 mL/mmol) and HCl 1 M (2.5 mL/mmol) were added to the reaction 
mixture, which was then extracted with CH2Cl2 (3 x 20 mL). The organic layer was 
washed with brine, and then dried on anhydrous Na2SO4. Removal of volatiles under 
reduced pressure afforded an oily residue which was subjected to column 
chromatography on silica-gel (hexane-EtOAc mixtures as eluent) to yield the desired 
products 16-18. 
4.2.10. Experimental procedure for the synthesis of ureas T.9-T.17. 
A solution of the corresponding chloroaniline (0.5 mmol) in dry THF (4 mL/mmol) 
was treated with Et3N (5.4 mmol) under inert atmosphere. After stirring the mixture for 
5 min, the corresponding previously prepared carbamate (0.5 mmol) was added dropwise 
as a solution in THF (10 mL/mmol). The resulting mixture was then stirred in the dark at 
40-50 ºC for 24-72 h (TLC monitoring). After this time, CH2Cl2 (15 mL) and HCl 1M 
were added to the reaction mixture, which was then extracted with CH2Cl2 (2 x 10 mL). 
The organic layer was washed with brine and then dried on anhydrous Na2SO4. Removal 
of volatiles under reduced pressure afforded an oily residue which was subjected to 
column chromatography on silica-gel (hexane-EtOAc mixtures as eluent) to afford the 
desired products. Detailed analytical data ate given in the Supplementary Material. 
4.3. Biological studies 
4.3.1. Cell culture 
Cell culture media were purchased from Gibco (Grand Island, NY). Fetal bovine serum 
(FBS) was obtained from Harlan-Seralab (Belton, U.K.). Supplements and other 
chemicals not listed in this section were obtained from Sigma Chemical Co. (St. Louis, 
MO). Plastics for cell culture were supplied by Thermo Scientific BioLite. All tested 
compounds were dissolved in DMSO at a concentration of 10 mM and stored at −20°C 
until use. 
HT-29, MCF-7, HeLa, A549 and HEK-293 cell lines were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) containing glucose (1 g/L), glutamine (2 mM), 
penicillin (50 μg/mL), streptomycin (50 μg/mL), and amphotericin B (1.25 μg/mL), 
supplemented with 10% FBS. HMEC-1 cell line was maintained in Dulbecco’s modified 
Eagle’s medium (DMEM)/Low glucose containing glutamine (2 mM), penicillin (50 
μg/mL), streptomycin (50 μg/mL), and amphotericin B (1.25 μg/mL), supplemented with 
10% FBS. For the development of tube formation assays in Matrigel, HMEC-1 cells were 
cultured in EGM-2MV Medium supplemented with EGM-2MV SingleQuots. 
4.3.2. Cell proliferation assay 
In 96-well plates, 3 × 103 (HeLa, A549, HMEC-1, HEK-293) or 5 × 103 (HT-29, MCF-
7) cells per well were incubated with serial dilutions of the tested compounds in a total 
volume of 100 μL of their respective growth media. The 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT; Sigma Chemical Co.) dye reduction assay in 96-
well microplates was used, as previously described [21]. After 2 days of incubation (37 
°C, 5% CO2 in a humid atmosphere), 10 μL of MTT (5 mg/mL in phosphate-buffered 
saline, PBS) was added to each well, and the plate was incubated for a further 3 h (37 °C). 
After that, the supernatant was discarded and replaced by 100 µL of DMSO to dissolve 
formazan crystals. The absorbance was then read at 540 nm by spectrophotometry. For 
all concentrations of compound, cell viability was expressed as the percentage of the ratio 
between the mean absorbance of treated cells and the mean absorbance of untreated cells. 
Three independent experiments were performed, and the IC50 values (i.e., concentration 
half inhibiting cell proliferation) were graphically determined using GraphPad Prism 4 
software. 
4.3.3. Apoptosis assay 
Apoptosis was determined by quantifying FITC-Annexin V translocation by means of 
flow cytometry. A549 cells were incubated with compounds for 24 h and then stained 
following instructions of BD Apoptosis DetectionTM Kit. Analysis was performed with a 
BD AccuriTM C6 flow cytometer. 
4.3.4. VEGFR-2 quantification by flow cytometry 
VEGFR-2 was determined quantifying Alexa Fluor® 647 Mouse Anti-Human CD309 
(VEGFR-2) by means of flow cytometry. To detect membrane VEGFR-2, cells were 
incubated with compounds for 24 h and then they were collected, fixed and stained with 
Alexa Fluor® 647 Mouse Anti-Human CD309 (VEGFR-2). For the detection of total 
VEGFR-2 (membrane and cytosolic), cells were incubated with compounds for 24 h, then 
lysates were obtained and stained with Alexa Fluor® 647 Mouse Anti-Human CD309 
(VEGFR-2). 
4.3.5. Total VEGFR-2 determination by immunofluorescence 
A549 cells were plated on cover glass and incubated with the different compounds for 
24 h. Then, they were permeabilized with PEM-Triton-X-100 0.5% and fixed in 3.7% 
formaldehyde. Direct immunostaining was carried out for 2 h at 37°C in darkness with 
Alexa Fluor® 647 Mouse Anti-Human CD309 (VEGFR-2). Then, cells were washed in 
PBS and cover glasses were mounted with 10 μL of Glycine/Glycerol buffer. Images were 
obtained by a confocal laser scanning microscope (CLSM) Leica SP5 with a Leica 
inverted microscope, equipped with a Plan-Apochromat 63x oil immersion objective 
(NA=1.4). Each image was recorded with the CLSM’s spectral mode selecting specific 
domains of the emission spectrum. Alexa Fluor®647 fluorophore was excited at 650 nm 
with an argon laser and its fluorescence emission was collected at 665 nm. 
4.3.6. phospho-VEGFR-2 quantification by ELISA 
For endothelial cells (HMEC-1): 5 x·105 cells/well were seeded in 6-well plates and 
once they were at 80% of their confluency, they were starved with medium containing 
0.1% of FBS for 24 h. Then, cells were incubated with the corresponding compounds for 
24 h and next cells were stimulated with 100 ng/ml of Recombinant VEGF-165 for 30 
min at 37ºC. After that, lysates were collected, protein quantification was carried out by 
Bradford test and, then, and phospho-VEGFR-2 was quantified using PathScan® 
Phospho-VEGFR-2(Tyr1175) Sandwich ELISA Kit according to the manufacturer’s 
instructions. For tumor cells (A549): 3·x 105 cells/well were seeded in 6-well plates and 
were incubated with the corresponding compounds at 10 μM for 24 h. After that, lysates 
were collected, protein quantification was carried out by Bradford test and, then, phospho-
VEGFR-2 was quantified using PathScan® Phospho-VEGFR-2(Tyr1175) Sandwich 
ELISA Kit according to the manufacturer’s instructions. 
4.3.7. p-Erk quantification by western blot assay 
From the lysates extracted in the previous experiment (5.3.6), 100 μg of proteins were 
subjected to gel electrophoresis using Bolt 4-12% Bis-Tris plus gels. Then, proteins were 
transferred to Hybond-P polyvinylidene difluoride (PVDF) membranes using the iBlot 
gel transfer system, and the resulting membranes were incubated first for 1 h at rt in 
blocking buffer (5% non-fat dry milk in TBS 1x containing 0.1% Tween) and 
subsequently overnight at 4 ºC in TBST buffer primary antibody solution (Anti-
ERK1+ERK2 phosphoT202+T204). After washing, membranes were incubated with the 
corresponding HRP-conjugated secondary antibody in blocking buffer for 1 h at rt. Next, 
membranes were washed extensively and immunoreactive proteins were detected by 
chemiluminescence (ImageQuant LAS500). 
4.3.8. Tube formation inhibition assay 
Wells of a 96-well μ-plate for angiogenesis were coated with 12 μL of Matrigel® (10 
mg/mL, BD Biosciences) at 4ºC. After gelatinization at 37ºC for 30 min, HMEC-1 cells 
were seeded at 2 x 104 cells/well in 35 μL of culture medium on top of the Matrigel and 
were incubated 30 min at 37ºC while are attached. Then, compounds were added 
dissolved in 35 μL of culture medium and after 20 h of incubation at 37ºC, tube 
destruction was evaluated. 
4.3.9. PD-L1 and c-Myc quantification by ELISA 
A549 cells were seeded (3·105 cells/well) in 6-well plates and were incubated with the 
corresponding compounds for 24 h. After that, lysates were collected, protein 
quantification was carried out by Bradford test and, then, PD-L1 and c-Myc were 
quantified using Human PD-L1 ELISA Kit 28-8 (ab214565) and c-Myc (Total) Human 
ELISA Kit (KHO2041), respectively, according to the manufacturer’s instructions. 
4.3.10. PD-L1 and c-Myc determination by immunofluorescence 
A549 cells were plated on cover glass and incubated with the different compounds for 
24 h. Then, they were permeabilized with PEM-Triton-X-100 0.5% and fixed in 3.7% 
formaldehyde. Direct immunostaining was carried out for 2 h at 37°C in darkness with 
Anti-PD-L1-AlexaFluor®647 and Anti-c-Myc-FITC. Then, cells were washed in PBS 
and cover glasses were mounted with 10 μL of Glycine/Glycerol buffer. Images were 
obtained by a confocal laser scanning microscope (CLSM) Leica SP5 with a Leica 
inverted microscope, equipped with a Plan-Apochromat 63x oil immersion objective 
(NA=1.4). Each image was recorded with the CLSM’s spectral mode selecting specific 
domains of the emission spectrum. Alexa Fluor®647 fluorophore was excited at 650 nm 
with an argon laser and its fluorescence emission was collected at 665 nm. FITC 
fluorophore was excited at 488 nm with an argon laser and its fluorescence emission was 
collected between 496 nm and 535 nm. 
4.3.11. Cell proliferation evaluation in co-cultures 
In 6-well plates, 5 x 104 tumor cells per well were seeded and incubated for 24 h with 
the tested compounds at 200 μM in a total volume of 1.5 mL in the presence of 2 × 105 
Jurkat T cells per well. Then, supernatant was discarded, tumor cells were collected with 
trypsin and counted using the Neubauer chamber. 
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List of captions 
Figure 1. Structure of sorafenib and non-peptidic inhibitors of PD-L1. 
Figure 2. Identified general structures able to interact with the kinase domain of VEGFR-
2 and PD-L1. The hydrogen bonds that can be formed with VEGFR-2 are indicated in 
red. The zones of the molecules that interact with the hydrophobic pockets of both binding 
sites are also indicated. 
Figure 3. A) Superposition of D.1 (orange), D.2 (light blue), D.3 (green) and sorafenib 
(grey) in the kinase domain of VEGFR-2. B). Superposition of D.1 (orange), D.2 (light 
blue), D.3 (green) and BMS-202 (violet) at the PD-L1 binding site. 
Figure 4. Potential multitarget inhibitors of VEFGR-2 and PD-L1. 
Scheme 1 
Table 1. Effect on VEGFR-2 in HMEC-1 cells. 
Table 2. Effect on VEGFR-2 in A549 cells. 
Table 3. p-VEGFR-2 and p-Erk1/2 detected in HMEC-1 cells. 
Figure 5. Representative Western blot of p-Erk1/2 detection in HMEC-1 cells. β-actin 
was used as internal control. 
Table 4. p-VEGFR-2 and p-Erk1/2 detected in A549 cells. 
Figure 6. Representative Western blot of p-Erk1/2 detection in A549 cells. β-actin was 
used as internal control. 
Table 5. Inhibition effect of tube formation. 
Table 6. PD-L1 and c-Myc detection in A549 cells. 
Figure 7. Inhibition of cell proliferation (%) in presence of Jurkat T cells. Data are 
representative of three experiments. 
Scheme 2 
Table 7. IC50 values (μM) for sunitinib, sorafenib, BMS-8 and derivatives T.9-T.17. 
Figure 8. Apoptotic effect (%) in A549 cells. Data are representative of three 
experiments. 
Table 8. Effect on VEGFR-2 expression in A549 cells. 
Figure 9. Effect on VEGFR-2 expression in A549 cells (A) DMSO, (B) T.13 and (C) 
T.14. 
Table 9. Effect on VEGFR-2 expression in HMEC-1 cells. 
Table 10. p-VEGFR-2 and p-Erk1/2 detected in A549 cells.  
Figure 10. Representative Western blot of p-Erk1/2 detection in A549 cells. β-actin was 
used as internal control. 
Table 11. Inhibition effect of tube formation. 
Figure 11. Effect of T.14 at 1, 0.1 and 0.01 µM concentrations (from left to right). 
Table 12. PD-L1 and c-Myc proteins detection in A549 cells. 
Figure 12. Effect on PD-L1 (red) and c-Myc (green) in A549 cells. (A) DMSO, (B) BMS-
8, (C) T.14. 
Figure 13. Inhibition of cell proliferation (%) in presence of Jurkat T cells. Data are 
























Sorafenib 46 ± 8 64 ± 4 
T.1 97 ± 14 105 ± 10 
T.2 74 ± 6 81 ± 14 
T.3 90 ± 4 102 ± 5 
T.4 79 ± 10 78 ± 1 
T.5 40 ± 10 55 ± 5 
T.6 79 ± 9 100 ± 11 
T.7 76 ± 4 91 ± 9 
T.8 97 ± 15 90 ± 7 








Sorafenib 92 ± 3 85 ± 5 
Sunitinib 66 ± 8 135 ± 14 
T.2 95 ± 3 86 ± 6 
T.4 98 ± 6 80 ± 8 
T.5 70 ± 4 61 ± 11 








Sorafenib 77 ± 9 80 ± 8 
T.1 100 ± 12 - 
T.2 70 ± 16 38 ± 14 
T.3 86 ± 3 72 ± 6 
T.4 >100 - 
T.5 >100 - 
T.6 83 ± 4 82 ± 11 
T.7 90 ± 10 - 
T.8 >100 - 











Sorafenib 84 ± 4 50 ± 7 
T.2 121 ± 11 99 ± 9 
T.3 125 ± 12 78 ± 7 
T.6 121 ± 16 119 ± 8 
T.7 112 ± 10 90 ± 13 















Data are representative of three experiments. 
  
Table 6 
Comp. % PD-L1 % c-Myc 
BMS-8 68 ± 5 60 ± 7 
T.1 83 ± 9 - 
T.2 70 ± 8 60 ± 8 
T.3 69 ± 10 73 ± 5 
T.4 80 ± 12 - 
T.5 >100 - 
T.6 82 ± 20 - 
T.7 90 ± 20 - 
T.8 66 ± 6 70 ± 8 













Inhibition of cell proliferation (%)





Comp. HT-29 MCF-7 HeLa A549 HMEC-1 HEK-293 
Sunitinib 3.8 ± 0.5 0.08 ± 0.02 7.8 ± 1.0 11 ± 2 7 ± 4 5.0 ± 0.8 
Sorafenib 17 ± 4 14 ± 4 6.1 ± 0.4 27 ± 2 34 ± 3 5.0 ± 0.7 
BMS-8 19 ± 2 20 ± 3 >100 6 ± 1 - 60 ± 10 
T.9 12 ± 4 19 ± 2 22 ± 3 21 ± 9 33.0 ± 0.6 6.5 ± 0.2 
T.10 20 ± 10 37.2 ± 0.8 10.5 ± 0.6 38 ± 3 32.9 ± 0.5 5 ± 2 
T.11 33 ± 5 17 ± 3 8 ± 1 29 ± 3 33 ± 3 20 ± 10 
T.12 47 ± 4 >100 >100 61 ± 3 >100 57 ± 3 
T.13 3.5 ± 0.6 4.3 ± 0.7 11.3 ± 0.7 7.7 ± 0.2 2 ± 1 2.4 ± 0.6 
T.14 0.52 ± 0.09 0.40 ± 0.09 0.7 ± 0.3 1.5 ± 0.9 1.8 ± 0.8 1.0 ± 0.4 
T.15 20 ± 3 >100 69 ± 5 24 ± 5 48 ± 7 90 ± 10 
T.16 14 ± 4 8.2 ± 0.6 16.5 ± 0.7 >200 50 ± 20 5.3 ± 0.9 
T.17 1.5 ± 0.1 15.3 ± 0.4 21 ± 1 >200 >200 1.8 ± 0.7 
IC50 values are expressed as the compound concentration that inhibits the cell growth by 50%. Data are the average 

























Sorafenib 92 ± 3 85 ± 5 
Sunitinib 66 ± 8 135 ± 14 
T.9 114 ± 20 177 ± 9 
T.10 102 ± 10 186 ± 10 
T.11 118 ± 3 100 ± 7 
T.12 109 ± 18 42 ± 9 
T.13 52 ± 10 32 ± 4 
T.14 56 ± 11 10 ± 2 
T.15 100 ± 19 100 ± 16 
T.16 97 ± 10 98 ± 3 
T.17 97 ± 11 96 ± 7 











Sorafenib 46 ± 8 64 ± 4 
T.12 76 ± 9 121 ± 8 
T.13 55 ± 8 106 ± 16 
T.14 56 ± 8 109 ± 17 








Sorafenib 84 ± 4 50 ± 7 
T.12 76 ± 3 100 ± 18 
T.13 75 ± 5 56 ± 12 
T.14 82 ± 3 66 ± 8 



























Comp.a % PD-L1 % c-Myc 
BMS-8 68 ± 5 60 ± 7 
T.9 83 ± 3 - 
T.10 92 ± 10 - 
T.11 75 ± 6 - 
T.12 74 ± 7 - 
T.13 49 ± 8 65 ± 12 
T.14 25 ± 9 37 ± 5 
T.15 61 ± 6 63 ± 11 
T.16 51 ± 9 51 ± 10 
T.17 38 ± 3 44 ± 6 
a T.9-T.14 were tested at 15 µM. BMS-8 and T.15-T.17 were tested at 100 µM. Data are the average (±SD) 

















Cell proliferation inhibition (%)
BMS-8 T.13 T.14 T.17
